In March 2012, Roy O’Connor LLP launched a proposed class action against Boiron Canada Inc., a wholly owned subsidiary of Boiron SA, a public company in France, and Shoppers Drug Mart Corporation relating to the marketing and sale of the homeopathic remedy sold under the brand name “Oscillococcinum” and variants of the same, including, but not exclusively, “Ocilla®”, “Oscillococcinum Children” and “Oscillo® Children” (“Oscillicoccinum”). According to Boiron, Oscillicoccinum is effective in relieving cold and flu symptoms and is described by Boiron as “a leading flu medicine”. The Statement of Claim alleges that, among other things, the Defendants breached several consumer protection statues in its marketing of Oscillicoccinum as the product contains virtually none of its purported active ingredient being namely Anas Barbarie Hepatis et Cordis extractum (namely the extract of the liver and heart of the Barbary Duck). As a result of the alleged breaches, it is alleged that the proposed class members have vastly overpaid for what is in essence a sugar pill.
The allegations in the Statement of Claim have yet to be proven in Court.
The plaintiff will bring a motion to have this action certified as class action. The time and place of the hearing of the certification motion will be posted on this website as soon as it scheduled by the Court.
More Information/Register as a Class Member
For more information about this action or to register as a class member please contact Roy O’Connor LLP at: